title: Which antidotes are available for the novel oral anticoagulants?
abstract: Use of novel (or target-specific) oral anticoagulants continues to increase. This article reviews idarucizumab and andexanet alfa, two antidotes that can be used to reverse anticoagulation in patients needing emergency surgery or with life-threatening bleeding.
authors.affiliation: Rebekah Thomas is an assistant professor in the PA program at Philadelphia College of Osteopathic Medicine's Georgia campus in Suwanee, Ga. Renzo Gonzalez is a student in the doctor of pharmacy program at Philadelphia College of Osteopathic Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Rebekah
authors.initials: R
authors.lastname: Thomas
authors.forename: Renzo
authors.initials: R
authors.lastname: Gonzalez
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D000931:Antidotes; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans
chemical_list: D000925:Anticoagulants; D000931:Antidotes